Oral News and Research

RSS

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration has approved SAVAYSA (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF).

8 Jan 2015

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.

8 Jan 2015

H&P Labs announces licensing agreement to develop oral drug therapy against Ebola

H&P Labs Inc. announced an agreement with Harvard University and Brigham and Women's Hospital to license two classes of compounds in order to develop an oral drug therapy against Ebola.

8 Jan 2015

Certain patients with type 2 diabetes, renal impairment discouraged from taking metformin

Many patients with type 2 diabetes in the United States may be discouraged from taking metformin—a proven, oral diabetes medicine—because the U.S. Food and Drug Administration inappropriately labels the drug unsafe for some patients also suffering from kidney problems, researchers from Penn Medicine and Weill Cornel Medical College report this week in a research letter published in JAMA Internal Medicine.

7 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

31 Dec 2014

Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it completed the design of the Rheumatoid Arthritis (RA) Phase III study of its lead drug candidate CF101.

31 Dec 2014

Supreme Court urged to reject IRS regulations authorizing tax subsidies for health insurance purchasers

The American Center for Law and Justice (ACLJ), which focuses on constitutional law, today filed an amicus brief with the U.S. Supreme Court urging the high court to reject IRS regulations illegally authorizing tax subsidies for purchasers of health insurance on federal healthcare exchanges.

31 Dec 2014

Three common health problems tied to oral health

Many people think that going to the dentist is all about getting a bright and shining smile. While this is an important aspect of dentistry, an experienced dentist like Farzad Feiz, DDS, of Calabasas Dental Group and California Dental Care can also help patients with their overall health.

27 Dec 2014

Tianyin Pharmaceutical releases unaudited preliminary financial results for Q1 FY 2015

Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) released unaudited preliminary financial results for the first quarter of fiscal year 2015.

25 Dec 2014

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

25 Dec 2014

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

AbbVie receives Health Canada approval for HOLKIRA PAK (ombitasvir/paritaprevir/ritonavir film-coated tablets; dasabuvir film-coated tablets), an all-oral, short-course (12 weeks for the majority of patients), interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with cirrhosis.

23 Dec 2014

Study emphasizes the importance of transparency in health communication for routine vaccination

A new study by Dr. Anat Gesser-Edelsburg, Dr. Yaffa Shir-Raz and Prof. Manfred S. Green from University of Haifa, School of Public Health, published in the Journal of Risk Research suggests that even parents who are not "vaccine refusers" and who usually comply with the routine vaccination programs may hesitate or refuse to vaccinate their children based on poor communication from the relevant healthcare provider, as well as concerns about the safety of the vaccine.

22 Dec 2014

Novo Nordisk gets positive CHMP opinion for expanded use of Tresiba in children with diabetes

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged one to 17 years with diabetes.

From Novo Nordisk 22 Dec 2014

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis.

21 Dec 2014

Oral budesonide suspension offers hope for pediatric patients with EoE

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

19 Dec 2014

Canopus BioPharma study confirms efficacy of CB008 drug for Ebola Virus inhibition

Canopus BioPharma Inc. today announces that it has completed crucial research in confirming efficacy of a prescription drug: CB008 for Ebola Virus inhibition.

19 Dec 2014

Certain complementary medicines may cause side effects, warns NPS MedicineWise

With new information from Melbourne’s Peter MacCallum Cancer Centre revealing that some complementary medicines can interact with cancer treatment, NPS MedicineWise reminds all Australians that complementary medicines can cause side effects, and interact with other over-the-counter and prescription medicines.

19 Dec 2014

LSDF announces $1.2 million in grants to foster advancement of promising health-related technologies

The Life Sciences Discovery Fund today announced $1.2 million in Proof of Concept grants to Washington-based organizations to foster the advancement of promising health-related technologies to commercial products. Also announced were two commercialization-focused awards, totaling $600,000, through a new funding program requiring external cash matching.

18 Dec 2014

Aging: A risk factor for malnutrition

Health care systems and providers are not attuned to older adults' malnutrition risk, and ignoring malnutrition exacts a toll on hospitals, patients, and payers, according to the latest issue of the What's Hot newsletter from The Gerontological Society of America.

18 Dec 2014

Oral News and Research

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

FDA approves RYTARY for Parkinson's disease treatment

H&P Labs announces licensing agreement to develop oral drug therapy against Ebola

Certain patients with type 2 diabetes, renal impairment discouraged from taking metformin

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Supreme Court urged to reject IRS regulations authorizing tax subsidies for health insurance purchasers

Three common health problems tied to oral health

Tianyin Pharmaceutical releases unaudited preliminary financial results for Q1 FY 2015

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Study emphasizes the importance of transparency in health communication for routine vaccination

Novo Nordisk gets positive CHMP opinion for expanded use of Tresiba in children with diabetes

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

Oral budesonide suspension offers hope for pediatric patients with EoE

Canopus BioPharma study confirms efficacy of CB008 drug for Ebola Virus inhibition

Certain complementary medicines may cause side effects, warns NPS MedicineWise

LSDF announces $1.2 million in grants to foster advancement of promising health-related technologies

Aging: A risk factor for malnutrition

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News